Ceftazidime 500 Mg Fresenius, Ceftazidime 1 000 Mg Fresenius, Ceftazidime 2 000 Mg Fresenius 500 mg, 1 000 mg, 2 000 mg Powder for solution for Injection, Powder for solution for Injection or Infusion
PDF Leaflet Revision Date: 09 March 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of severe infections caused by susceptible organisms.
Dosage (summary)
Adults: 1-6 g/day; 1 g or 2 g IV/IM every 8-12 hours.
Special Populations
- Cystic fibrosis
- Elderly
- Renal impairment
Pregnancy & Breastfeeding
Not established; avoid in pregnancy and breastfeeding.
Key Drug Interactions
- Nephrotoxic agents (e.g., aminoglycosides)
- Probenecid
Contraindications
- Hypersensitivity to ceftazidime or u03b2-lactams
Common side effects
- Diarrhoea
- Rash
- Eosinophilia
Counselling Points
- Report any allergic reactions.
- Monitor for signs of diarrhoea.
- Avoid use in pregnancy unless necessary.
Serious warnings
- Serious hypersensitivity reactions
- Clostridium difficile-associated diarrhoea
Important Disclaimer
The Ceftazidime 500 Mg Fresenius, Ceftazidime 1 000 Mg Fresenius, Ceftazidime 2 000 Mg Fresenius 500 mg, 1 000 mg, 2 000 mg Powder for solution for Injection, Powder for solution for Injection or Infusion professional information leaflet below is the property of Fresenius Kabi South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
